Thermo Fisher Scientific has announced the launch of the Invitrogen™ Vivofectamine™ Delivery Solutions, an advanced lipid nanoparticle (LNP) technology designed to revolutionize non-viral nucleic acid delivery. This innovation aims to accelerate life science research and the development of genetic medicine, offering researchers and developers a robust solution to safely and effectively deliver RNA or DNA to target cells.

Developed from a library of over 6,000 chemically diverse ionizable lipids, Vivofectamine Delivery Solutions enable tailored in vivo delivery with unparalleled efficiency, specificity, and safety. This technology addresses the growing demand for non-viral delivery systems in response to the global validation of LNP-based COVID-19 mRNA vaccines and increasing concerns surrounding viral delivery methods.

A Leap Forward in Genetic Medicine Development
Delivering nucleic acids to specific organs or cells while maintaining their integrity is one of the greatest challenges in genetic medicine. Vivofectamine Delivery Solutions offer a safer, non-viral alternative, advancing applications in areas such as prophylactic and cancer vaccines, gene replacement, gene editing therapies, immune cell therapies, and stem cell research.

"With decades of expertise in lipid-based delivery technologies, our Invitrogen Vivofectamine Delivery Solutions represent a new era in in vivo nucleic acid delivery," said Tiffani Manolis, Vice President, Cell Biology, Thermo Fisher Scientific. "By combining advanced LNP technologies with tailored portfolios for research and drug development, we are empowering scientists to drive innovation in genetic medicine while reducing time and cost."

Tailored Solutions for Researchers and Developers
The Vivofectamine portfolio is designed to meet the needs of both academic researchers and drug developers:

• Basic Research Portfolio: Catalog LNP reagents for academic and institutional researchers.
• Drug Development Portfolio: Custom LNP reagents and services designed to meet the specific needs of biotechnology and biopharmaceutical companies.

Key Features and Benefits:

• Versatility: Developed through iterative cycles of rational lipid design, Vivofectamine LNPs offer various reagent formats, optimization services, and adaptable licensing options.
• Safety: Extensive preclinical testing in non-human primates and rats has demonstrated the safety and tolerability of Vivofectamine LNPs, benchmarked against leading clinical-stage LNPs.
• Proven Efficacy: Optimized for intramuscular delivery in vaccines and systemic delivery to the liver, with additional feasibility studies indicating potential applications in immune cells, muscles, tumors, eyes, and the central nervous system.

Driving Innovation in Nucleic Acid Delivery
Thermo Fisher’s Vivofectamine Delivery Solutions are intended for research use only and are poised to accelerate advancements in life science research and genetic medicine development globally. By addressing key challenges in nucleic acid delivery, this innovative LNP platform paves the way for groundbreaking therapies that could transform patient outcomes.